The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patients
On 22 January 2025, the European Commission approved an isatuximab combination for the treatment of newly diagnosed myeloma patients who are not eligible for a stem cell transplant in the EU. This follows a positive recommendation…